Autifony Therapeutics Announces £2.75m Collaboration with Universities of Manchester and Newcastle to Progress a First-in-Class Drug for Schizophrenia

London – UK – 1 July 2013 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a collaboration with research groups at the University of Manchester and Newcastle University to develop a novel, first-in-class Kv3 potassium channel modulator for the treatment of schizophrenia. The £2.75 million research collaboration is part-funded by the award of a £1.9 million grant to Autifony and the two Universities, by the UK’s innovation agency, the Technology Strategy Board. The award follows a successful funding application to the Biomedical Catalyst, jointly funded by the Technology Strategy Board and the Medical Research Council.